Basic Information
The company collaborates with Novartis on a nanoparticle candidate for Type 1 diabetes, with Parvus developing its proprietary Navacims to help the body's immune system distinguish between pathogens and self.
Gryphon Pharmaceuticals,Inc.
Maryland,United States of America
unclear
--
--
--